{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:23:22Z","timestamp":1767983002001,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Botulinum toxin A detrusor injection (BoNT\/A-DI) is used in patients with overactive bladder (OAB) or neurogenic bladder due to multiple sclerosis (MS) or after spinal cord injury. The procedure is generally performed under local anaesthesia. We examined the influence of BoNT\/A-DI on blood pressure, the most important autonomic parameter in awake patients, as a potential risk factor for cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material &amp; Methods<\/jats:title>\n                    <jats:p>Patients with OAB or spontaneous voiding with neurogenic detrusor overactivity (NDO) due to MS in whom BoNT\/A-DI was planned under local anaesthesia, vital parameters (systolic, diastolic, and mean blood pressure; heart rate; and rate pressure product [RPP]) were recorded before, during, and after the procedure. Participants with and without previously known hypertension were compared, along with those with initial versus repeat injections, with a focus on the high-risk group, which comprised the 20% of patients with the highest baseline blood pressure values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy patients were included (mean age: 64.0, median age: 66, range: 27\u201386 years), and two were excluded because their initial blood pressure values were too high. Sixty patients had OAB, and eight had NDO due to MS; twenty-two patients had a history of hypertension. A total of 40 patients received the first injection, and 28 received a repeat injection. Systolic blood pressure increased significantly by an average of 9.8 mmHg. However, in the hypertensive patients, systolic blood pressure rose by an average of 19.4 mmHg; isolated peak systolic values rose by up to 232 mmHg, and peak diastolic values rose by up to 128 mmHg. Cardiac stress (measured by rate pressure product [RPP]) in these patients increased significantly (RPP\u2009=\u200917.6 versus 7.2 in the non-hypertensive group). In the 20% of patients with the highest resting blood pressure values, systolic blood pressure rose to an average of 187.4 mmHg (15.1 mmHg compared with resting blood pressure), and cardiac workload increased by 17. No significant differences were observed between patients who received initial and repeat injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians who administer BoNT\/A-DI should monitor blood pressure during the procedure and be aware of the risk of potentially significantly elevated blood pressure values during BoNT\/A DI, especially in patients with a medical history of hypertension. Significantly elevated pre-interventional blood pressure values should receive an internal medicine consultation timely before the intervention to prevent cardiovascular risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05596-3","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T06:36:32Z","timestamp":1743834992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood pressure can be seriously elevated during botulinum toxin A detrusor injection"],"prefix":"10.1007","volume":"43","author":[{"given":"Heinrich","family":"Schulte-Baukloh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Schlomm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Ralla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"Borgmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"H\u00f6ppner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"2","key":"5596_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation Sub-committee of the international continence society. Neurourol Urodyn 21(2):167\u2013178","journal-title":"Neurourol Urodyn"},{"issue":"9","key":"5596_CR2","first-page":"728","volume":"15","author":"J Yeaw","year":"2009","unstructured":"Yeaw J et al (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15(9):728\u2013740","journal-title":"J Manag Care Pharm"},{"issue":"3","key":"5596_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amjmed.2005.12.011","volume":"119","author":"DR Staskin","year":"2006","unstructured":"Staskin DR, MacDiarmid SA (2006) Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 119(3):9\u201315","journal-title":"Am J Med"},{"issue":"4","key":"5596_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/toxins8040120","volume":"8","author":"JF Jhang","year":"2016","unstructured":"Jhang JF, Kuo HC (2016) Botulinum toxin A and lower urinary tract dysfunction: pathophysiology and mechanisms of action. Toxins (Basel) 8(4):120","journal-title":"Toxins (Basel)"},{"issue":"1","key":"5596_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00192-020-04423-0","volume":"32","author":"R Hamid","year":"2021","unstructured":"Hamid R et al (2021) OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice. Int Urogynecol J 32(1):65\u201374","journal-title":"Int Urogynecol J"},{"issue":"6","key":"5596_CR6","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 189(6):2186\u20132193","journal-title":"J Urol"},{"issue":"6","key":"5596_CR7","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/nau.25221","volume":"42","author":"E Farrelly","year":"2023","unstructured":"Farrelly E, Hamid R, Lorenzo-Gomez MF, Schulte-Baukloh H, Yu J, Patel A, Nelson M (2023) One treatment with OnabotulinumtoxinA relieves symptoms of overactive bladder in patients refractory to one or more oral medications. Neurourol Urodyn 42(6):1203\u20131213","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"5596_CR8","first-page":"450","volume":"11","author":"M Whitman","year":"2021","unstructured":"Whitman M, Jenkins C (2021) Rate pressure product, age predicted maximum heart rate or heart rate reserve. Which one better predicts cardiovascular events following exercise stress echocardiography? Am J Cardiovasc Dis 11(4):450\u2013457","journal-title":"Am J Cardiovasc Dis"},{"issue":"4","key":"5596_CR9","doi-asserted-by":"publisher","first-page":"e067951","DOI":"10.1136\/bmjopen-2022-067951","volume":"13","author":"ZH Jiang","year":"2023","unstructured":"Jiang ZH, Aierken A, Wu TT, Zheng YY, Ma YT, Xie X (2023) Rate pressure product as a novel predictor of long-term adverse outcomes in patients after percutaneous coronary intervention: a retrospective cohort study. BMJ Open 13(4):e067951","journal-title":"BMJ Open"},{"issue":"1","key":"5596_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/nau.25061","volume":"42","author":"N Faure Walker","year":"2023","unstructured":"Faure Walker N et al (2023) Interventions to improve tolerability of local anesthetic intradetrusor botulinum toxin injections: A systematic review. Neurourol Urodyn 42(1):23\u201332","journal-title":"Neurourol Urodyn"},{"issue":"15","key":"5596_CR11","first-page":"1839","volume":"113","author":"SE Kjeldsen","year":"1993","unstructured":"Kjeldsen SE et al (1993) [White coat hypertension and blood pressure measurement at home]. Tidsskr nor Laegeforen 113(15):1839\u20131843","journal-title":"Tidsskr nor Laegeforen"},{"issue":"6","key":"5596_CR12","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1161\/HYPERTENSIONAHA.114.05038","volume":"65","author":"L Zhang","year":"2015","unstructured":"Zhang L et al (2015) Strategies for classifying patients based on office, home, and ambulatory blood pressure measurement. Hypertension 65(6):1258\u20131265","journal-title":"Hypertension"},{"key":"5596_CR13","doi-asserted-by":"crossref","unstructured":"Schulte-Baukloh H, Apostolidis A, Weiss C, Schlomm T, Weinberger S, Hoeppner D, Haberecht K, Waskow C, Borgmann H, Neymeyer J, Ralla B (2024) Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection. Toxins, 16. In press","DOI":"10.3390\/toxins16110462"},{"key":"5596_CR14","doi-asserted-by":"publisher","first-page":"e941351","DOI":"10.12659\/MSM.941351","volume":"29","author":"M Karalar","year":"2023","unstructured":"Karalar M, Demirbas A, Gercek O, Topal K, Keles I (2023) Impact of preoperative Video-Based education on anxiety levels in patients with renal stones scheduled for flexible ureteroscopic lithotripsy: A comparative study using APAIS and STAI. Med Sci Monit 29:e941351","journal-title":"Med Sci Monit"},{"issue":"8","key":"5596_CR15","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/nau.24519","volume":"39","author":"ESR Pereira","year":"2020","unstructured":"Pereira ESR et al (2020) Alkalinized Lidocaine solution as a first-line local anesthesia protocol for intradetrusor injection of onabotulinum toxin A: results from a double-blinded randomized controlled trial. Neurourol Urodyn 39(8):2471\u20132479","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"5596_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/sj.sc.3101593","volume":"42","author":"B Schurch","year":"2004","unstructured":"Schurch B, Reitz A, Tenti G (2004) Electromotive drug administration of Lidocaine to anesthetize the bladder before botulinum-A toxin injections into the detrusor. Spinal Cord 42(6):338\u2013341","journal-title":"Spinal Cord"},{"key":"5596_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.autneu.2017.05.002","volume":"209","author":"KC Eldahan","year":"2018","unstructured":"Eldahan KC, Rabchevsky AG (2018) Autonomic dysreflexia after spinal cord injury: systemic pathophysiology and methods of management. Auton Neurosci 209:59\u201370","journal-title":"Auton Neurosci"},{"issue":"5","key":"5596_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/01.HYP.14.5.511","volume":"14","author":"J Fagius","year":"1989","unstructured":"Fagius J, Karhuvaara S (1989) Sympathetic activity and blood pressure increases with bladder distension in humans. Hypertension 14(5):511\u2013517","journal-title":"Hypertension"},{"issue":"5","key":"5596_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4082\/kjfm.2011.32.5.306","volume":"32","author":"EJ Choi","year":"2011","unstructured":"Choi EJ et al (2011) The impact of bladder distension on blood pressure in middle aged women. Korean J Fam Med 32(5):306\u2013310","journal-title":"Korean J Fam Med"},{"issue":"1","key":"5596_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.juro.2012.02.2561","volume":"188","author":"K Stav","year":"2012","unstructured":"Stav K et al (2012) Autonomic response during bladder hydrodistention in patients with bladder pain syndrome. J Urol 188(1):117\u2013121","journal-title":"J Urol"},{"key":"5596_CR21","doi-asserted-by":"crossref","unstructured":"Dai Y et al (2019) Short-Term and Long-Term blood pressure changes and the risk of All-Cause and cardiovascular mortality, vol 2019. BioMed Research International, p 5274097. 1","DOI":"10.1155\/2019\/5274097"},{"issue":"33","key":"5596_CR22","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B et al (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021 -3104.22","journal-title":"Eur Heart J"},{"issue":"6","key":"5596_CR23","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: A report of the American college of cardiology\/american heart association task force on clinical practice guidelines. Hypertension 71(6):1269\u20131324","journal-title":"Hypertension"},{"issue":"7451","key":"5596_CR24","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/bmj.328.7451.1279-c","volume":"328","author":"JH Tanne","year":"2004","unstructured":"Tanne JH (2004) European guidelines on hypertension more flexible than those in united States. BMJ 328(7451):1279","journal-title":"BMJ"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05596-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05596-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05596-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:53:17Z","timestamp":1767966797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05596-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5596"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05596-3","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"211"}}